Hyperandrogenism and insulin resistance, not changes in body weight, mediate the development of endothelial dysfunction in a female rat model of polycystic ovary syndrome (PCOS)

Endocrinology (United States)

Volumn 156, Issue 11, 2015, Pages 4071-4080

  Hurliman, Amanda ^a,e   Brown, Jennifer Keller ^a,d   Maille, Nicole ^b   Mandala, Maurizio ^b,c   Casson, Peter ^a,d   Osol, George ^b  

^a Division of Reproductive Endocrinology and Infertility   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF CALABRIA   (Italy)

^d Northeastern Reproductive Medicine   (United States)

^e Oregon Reproductive Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; FLUTAMIDE; GLUCOSE; INSULIN; METFORMIN; ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RAT; STEROID BLOOD LEVEL; WEIGHT GAIN; ANIMAL; ARTERY; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; TIME FACTOR; VASCULAR ENDOTHELIUM; VASODILATATION; WISTAR RAT;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; ARTERIES; BLOOD PRESSURE; BODY WEIGHT; DIHYDROTESTOSTERONE; ENDOTHELIUM, VASCULAR; FEMALE; FLUTAMIDE; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; RANDOM ALLOCATION; RATS, WISTAR; TIME FACTORS; VASODILATION;

EID: 84946088805     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1159     Document Type: Article

References (49)

1. Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The poly-cystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171:P1-P29.
2. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement bythe Androgen Excessand Polycystic Ovary Syndrome(AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95:2038-2049.
3. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J. 2009;73:595-601.
4. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054-2059.
5. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009;196: 193-222.
6. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of en-dothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241.
7. Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syn-drome:ameta-Analysisofthe observational studies. Clin Endocrinol (Oxf). 2013;78:438-446.
8. Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endo-thelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:5088-5095.
9. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syn-dromeisassociatedwith endothelial dysfunction. Circulation. 2001; 103:1410-1415.
10. Sorensen MB, Franks S, Robertson C, Pennell DJ, Collins P. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors. Clin Endocrinol (Oxf). 2006;65:655-659.
11. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:742-746.
12. Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ. A comprehensive assessment of endothelial functionin overweight women with and without polycystic ovary syndrome. Clin Sci (Lond). 2009; 116:761-770.
13. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in poly-cystic ovary syndrome. Reproduction. 2015;149:R219-R227.
14. Keller J, Mandala M, Casson P, Osol G. Endothelial dysfunction in a rat model of PCOS: evidence of increased vasoconstrictor prosta-noid activity. Endocrinology. 2011;152:4927-4936.
15. Manneras L, Cajander S, Holmang A, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007;148:3781-3791.
16. Verma S, McNeill JH. Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol. 1994;266: H714-H719.
17. Cacho J, Sevillano J, de Castro J, Herrera E, Ramos MP. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. Am J Physiol Endocrinol Metab. 2008;295:E1269-E1276.
18. Muniyappa R, Chen H, Muzumdar RH, et al. Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsuline-mic euglycemic clamp estimates in rats. Am J Physiol Endocrinol Metab. 2009;297:E1023-E1029.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and/3-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
20. Sprung VS, Jones H, Pugh CJ, et al. Endothelial dysfunction in hy-perandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin Sci (Lond). 2014;126:67-74.
21. Dokras A, Jagasia DH, Maifeld M, Sinkey CA, VanVoorhis BJ, Haynes WG. Obesity and insulin resistance but not hyperandro-genism mediates vascular dysfunction in women with polycystic ovary syndrome. Fertil Steril. 2006;86:1702-1709.
22. Manneras-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96:E304-E311.
23. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18: 266-272.
24. Blouin K, Veilleux A, Luu-The V, Tchernof A. Androgen metabolism in adipose tissue: recent advances. Mol Cell Endocrinol. 2009; 301:97-103.
25. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
26. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPAR7 activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR7 as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999;19:546-551.
27. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome prolif-erator-Activated receptor activators inhibit thrombin-induced en-dothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85: 394-402.
28. Brown JD, Plutzky J. Peroxisome proliferator-Activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115:518-533.
29. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162:193-212.
30. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-Acti-vated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55:496-505.
31. Detaille D, Guigas B, Chauvin C, et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54:2179-2187.
32. Huang NL, Chiang SH, Hsueh CH, Liang YJ, Chen YJ, Lai LP. Metformin inhibits TNF-A-induced IKB kinase phosphorylation, IB-A degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol. 2009;134: 169-175.
33. Diamanti-Kandarakis E, Spritzer PM, Sir-Petermann T, Motta AB. Insulin resistance and polycystic ovary syndrome through life. Curr Pharm Des. 2012;18:5569-5576.
34. Ressler IB, Grayson BE, Seeley RJ. Metabolic, behavioral, and reproductive effects of vertical sleeve gastrectomy in an obese rat model of polycystic ovary syndrome. Obes Surg. 2014;24:866-876.
35. Nacul AP, Andrade CD, Schwarz P, de Bittencourt PI Jr, Spritzer PM. Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol. 2007;133:191-196.
36. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004;89:5592-5596.
37. Orio F Jr, Palomba S, Cascella T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89: 4588-4593.
38. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152:749-756.
39. Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab. 2005;90:6072-6076.
40. Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2011;95:203-209.
41. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care. 2007;30:471-478.
42. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism. 1995;44:525-531.
43. Sahin I, Serter R, Karakurt F, et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecol Endocrinol. 2004;19:115-124.
44. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: increased peripheral 5a-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2760-2766.
45. Silfen ME, Denburg MR, Manibo AM, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003;88:4682-4688.
46. Fritz MA SL. Clincial Gynecologic Endocrinology and Infertility. 8th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams; 2011.
47. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-ino-sitol) for women with polycystic ovary syndrome, oligo amenor-rhoea and subfertility. Cochrane Database Syst Rev. 2012;5: CD003053.
48. Carlsen SM, Vanky E. Metformin influence on hormone levels at birth, in PCOS mothers and their newborns. Hum Reprod. 2010; 25:786-790.
49. Kjotrod SB, Sunde A, von During V, Carlsen SM. Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome. Fertil Steril. 2009; 91:500-508.